It has been reported that miR-133a was down-regulated in pressure overload hypertrophy [103] and diabetes [106], while miR-133a overexpression, reducing ERK1/2 activation, can alleviate cardiac fibrosis. The gene discussed is MAPK3; the disease is diabetes mellitus.